Review of Drug Quality and Security Act of 2013: The Drug Supply Chain Security Act (DSCSA)

The Drug Supply Chain Security Act (DSCSA) signed into law in November 27, 2013 by president Obama creates a uniform national standard for tracing drug products through the supply chain. The goal of DQSA is to enhance FDA’s ability to help protect consumers by detecting and removing potential dange...

Full description

Bibliographic Details
Main Authors: Elona Gjini, Albert I Wertheimer
Format: Article
Language:English
Published: University of Minnesota Libraries Publishing 2016-10-01
Series:INNOVATIONS in Pharmacy
Subjects:
Online Access:https://pubs.lib.umn.edu/index.php/innovations/article/view/462
id doaj-b8e3d13fa49d40859867bf38ba1ba4e0
record_format Article
spelling doaj-b8e3d13fa49d40859867bf38ba1ba4e02020-11-25T00:20:40ZengUniversity of Minnesota Libraries PublishingINNOVATIONS in Pharmacy2155-04172016-10-017310.24926/iip.v7i3.462Review of Drug Quality and Security Act of 2013: The Drug Supply Chain Security Act (DSCSA)Elona Gjini0Albert I Wertheimer1Temple UniversityTemple University The Drug Supply Chain Security Act (DSCSA) signed into law in November 27, 2013 by president Obama creates a uniform national standard for tracing drug products through the supply chain. The goal of DQSA is to enhance FDA’s ability to help protect consumers by detecting and removing potential dangerous products from the pharmaceutics distribution supply chain. A new electronic, interoperable system will identify and trace only prescription drugs in the finished form for human use while distributed in the United States. The purpose of this review was to shed light on a complex and complicated process that it will require cooperation between FDA and drug manufactures, wholesale drug distributors, repackagers and dispensers. The implementation of the DSCSA is based on several law requirements and FDA has developed a schedule with time frames for each of them to be executed over a 10-year period. From this review, FDA recommendations are provided through the FDA Guidance on Identifying Suspect Product document to help trading partners and provide information about the risk of suspect drugs entering the supply chain. Moreover, FDA organized on April 5-6, 2016 in Silver Spring, MD a public workshop to gather valuable feedback from stakeholders who shared their input about the implementation of the new electronic system and its requirements. By the end of 2023, a unified system will provide easier data exchange and less errors, and will increase the safety and security of the pharmaceutical distribution supply chain.   Type: Student Project https://pubs.lib.umn.edu/index.php/innovations/article/view/462Drug Supply Chain Security Act, national standard, unique product identifier, identifying suspect product, FDA public workshop
collection DOAJ
language English
format Article
sources DOAJ
author Elona Gjini
Albert I Wertheimer
spellingShingle Elona Gjini
Albert I Wertheimer
Review of Drug Quality and Security Act of 2013: The Drug Supply Chain Security Act (DSCSA)
INNOVATIONS in Pharmacy
Drug Supply Chain Security Act, national standard, unique product identifier, identifying suspect product, FDA public workshop
author_facet Elona Gjini
Albert I Wertheimer
author_sort Elona Gjini
title Review of Drug Quality and Security Act of 2013: The Drug Supply Chain Security Act (DSCSA)
title_short Review of Drug Quality and Security Act of 2013: The Drug Supply Chain Security Act (DSCSA)
title_full Review of Drug Quality and Security Act of 2013: The Drug Supply Chain Security Act (DSCSA)
title_fullStr Review of Drug Quality and Security Act of 2013: The Drug Supply Chain Security Act (DSCSA)
title_full_unstemmed Review of Drug Quality and Security Act of 2013: The Drug Supply Chain Security Act (DSCSA)
title_sort review of drug quality and security act of 2013: the drug supply chain security act (dscsa)
publisher University of Minnesota Libraries Publishing
series INNOVATIONS in Pharmacy
issn 2155-0417
publishDate 2016-10-01
description The Drug Supply Chain Security Act (DSCSA) signed into law in November 27, 2013 by president Obama creates a uniform national standard for tracing drug products through the supply chain. The goal of DQSA is to enhance FDA’s ability to help protect consumers by detecting and removing potential dangerous products from the pharmaceutics distribution supply chain. A new electronic, interoperable system will identify and trace only prescription drugs in the finished form for human use while distributed in the United States. The purpose of this review was to shed light on a complex and complicated process that it will require cooperation between FDA and drug manufactures, wholesale drug distributors, repackagers and dispensers. The implementation of the DSCSA is based on several law requirements and FDA has developed a schedule with time frames for each of them to be executed over a 10-year period. From this review, FDA recommendations are provided through the FDA Guidance on Identifying Suspect Product document to help trading partners and provide information about the risk of suspect drugs entering the supply chain. Moreover, FDA organized on April 5-6, 2016 in Silver Spring, MD a public workshop to gather valuable feedback from stakeholders who shared their input about the implementation of the new electronic system and its requirements. By the end of 2023, a unified system will provide easier data exchange and less errors, and will increase the safety and security of the pharmaceutical distribution supply chain.   Type: Student Project
topic Drug Supply Chain Security Act, national standard, unique product identifier, identifying suspect product, FDA public workshop
url https://pubs.lib.umn.edu/index.php/innovations/article/view/462
work_keys_str_mv AT elonagjini reviewofdrugqualityandsecurityactof2013thedrugsupplychainsecurityactdscsa
AT albertiwertheimer reviewofdrugqualityandsecurityactof2013thedrugsupplychainsecurityactdscsa
_version_ 1725365980532572160